Search

배경: Solid organ transplant recipients elicit decreased antibody responses mainly due to their weakened immune system. However, data are limited on antibody responses after the primary series of coronavirus disease 2019 (COVID-19) vaccines among recipients with solid organ transplant types. Thus, we compared the antibody responses after three COVID-19 vaccine doses between liver (LT) and kidney transplant (KT) recipients. 방법: We prospectively enrolled solid-organ transplant recipients who received three COVID-19 vaccine doses from June 2021 to February 2022 and measured S1-specific immunoglobulin G antibodies using an enzyme-linked immunosorbent assay. 결과: Seventy-six LT and 17 KT recipients were included in the final analysis. KT recipients showed consistently decreased antibody responses even after third dose vaccination (86.2% and 52.9%, P=0.008) and decreased antibody titer (423.0 [99.6–2057.0] vs. 19.7 IU/mL [6.9–339.4], P=0.006) than that of LT recipients. Mycophenolic acid was a significant risk factor for seropositive antibody response after the third dose vaccine in multivariable analysis (odds ratio 0.06, 95% confidence interval 0.00-0.39; P=0.02). 결론: We found a weaker antibody response despite the completion of the primary series of COVID-19 vaccines in KT recipients than that in LT recipients; mycophenolic acid use in KT recipients might be the main contributor to this observation. [ABSTRACT FROM AUTHOR]